Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 2/2017

01-02-2017 | Neurological Infections (J Lyons, Section Editor)

Infectious Complications of Novel Multiple Sclerosis Therapies

Authors: S. N. Levin, T. B. Kaplan

Published in: Current Infectious Disease Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system most often characterized by clinical relapses and periods of remission.

Recent Findings

The past decade has seen a dramatic increase in disease-modifying therapies for MS. Fourteen FDA-approved immunomodulatory drugs are currently available, and more medications are in development. A growing number of reported opportunistic infections, including progressive multifocal leukoencephalopathy (PML), highlight the serious complications of these new drugs and the need for specific screening guidelines.

Summary

Using data from Phase II and III randomized controlled trials, case reports, drug manufacturing data, and clinical experience, we outline the most common and serious infections associated with novel MS therapies.
Literature
1.
Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64:1336–42.CrossRefPubMed
2.
Leussink VI, Zettl UK, Jander S, et al. Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol. 2002;103:131–6.CrossRefPubMed
3.
Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.CrossRefPubMed
4.
Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–23.CrossRefPubMed
5.
Schiess N, Zong J, Hayward G, et al. Reactivation of herpes virus in multiple sclerosis patients on natalizumab therapy [P03.163]. Seattle: American Academy of Neurology; 2009.
6.
7.
Kwiatkowski A, Gallois J, Bilbault N, et al. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler. 2012;18:909–11.CrossRefPubMed
8.
Fine AJ, Sorbello A, Kortepeter C, et al. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis. 2013;57:849–52.CrossRefPubMed
9.
Bourre B, Lefaucheur R, Ahtoy P, et al. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology. 2013;81:1966–7.CrossRefPubMed
10.
11.
Zecca C, Nessi F, Bernasconi E, et al. Ocular toxoplasmosis during natalizumab treatment. Neurology. 2009;73:1418–9.CrossRefPubMed
12.
Gutwinski S, Erbe S, Munch C, et al. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology. 2010;74:521–3.CrossRefPubMed
13.
Valenzuela RM, Pula JH, Garwacki D, et al. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J Neurol Sci. 2014;340:109–11.CrossRefPubMed
14.
Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–74.CrossRefPubMed
15.
Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–81.CrossRefPubMed
16.
Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–8.CrossRefPubMed
17.
Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924–33.CrossRefPubMedPubMedCentral
18.
Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab—unforeseen consequences. N Engl J Med. 2005;353:414–6.CrossRefPubMed
19.
Lindberg RL, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol. 2008;194:153–64.CrossRefPubMed
20.
Houff SA, Berger J, Major EO. Response to Linberg et al. natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008;204:155–6; author reply 157
21.
Major EO. Reemergence of PML in natalizumab-treated patients—new cases, same concerns. N Engl J Med. 2009;361:1041–3.CrossRefPubMed
22.
23.
Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80.CrossRefPubMed
24.
Koendgen H, Chang I, Sperling B, et al. New algorithm to estimate risk of natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) in anti-JCV antibody positive patients: analyses of clinical trial data to provide further temporal precision and inform clinical practice [P1249]. 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. London, UK; 2016.
25.
Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802–12.CrossRefPubMed
26.
•• McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117–25. McGuigan and colleagues outline practical consensus guidelines for monitoring patients on natalizumab based on current evidence. The authors break down the risk of PML using JCV antibody titers, previous immunosuppressant exposure, and duration of natalizumab therapy.PubMed
27.
Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–46.CrossRefPubMed
28.
Ryschkewitsch CF, Jensen PN, Monaco MC, et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2010;68:384–91.CrossRefPubMedPubMedCentral
29.
Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun Rev. 2016;15:714–8.CrossRefPubMed
30.
Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.CrossRefPubMed
31.
Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–71.CrossRefPubMed
32.
Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909–20.CrossRefPubMedPubMedCentral
33.
Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10:816–24.CrossRefPubMed
34.
Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68:1156–64.CrossRefPubMedPubMedCentral
35.
Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40.CrossRefPubMedPubMedCentral
36.
Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425–37.CrossRefPubMedPubMedCentral
37.
38.
Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9:44–52.CrossRefPubMedPubMedCentral
39.
Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779–87.CrossRefPubMed
40.
Hauser S, Comi G, Hartung HP, et al. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis – results of the phase III double-blind, interferon beta-1a-controlled OPERA I and II Studies. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Barcelona, Spain; 2015.
41.
Montalban X, Hemmer B, Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis – results of the phase III, double-blind, placebo-controlled ORATORIO Study. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Barcelona, Spain; 2015.
42.
Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65:2368–79.CrossRefPubMed
43.
Emery P, Rigby W, Tak PP, et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014;9, e87379.CrossRefPubMedPubMedCentral
44.
45.
De Mercanti S, Rolla S, Cucci A, et al. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016;3, e194.CrossRefPubMedPubMedCentral
46.
Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28.CrossRefPubMed
47.
Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39.CrossRefPubMed
48.
49.
Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43:16–24.CrossRefPubMed
50.
Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007;44:204–12.CrossRefPubMed
51.
Vu T, Carrum G, Hutton G, et al. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39:705–9.CrossRefPubMed
52.
Rau D, Lang M, Harth A, et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis—report of two cases. Int J Mol Sci. 2015;16:14669–76.CrossRefPubMedPubMedCentral
53.
Penkert H, Delbridge C, Wantia N, et al. Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol. 2016;73:757–9.CrossRefPubMed
54.
Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69:759–77.CrossRefPubMed
55.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.CrossRefPubMed
56.
Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.CrossRefPubMed
57.
Francis G, Kappos L, O’Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20:471–80.CrossRefPubMed
58.
Cohen JA, Kappos L, Selmaj K, et al. Long-term safety and effectiveness of fingolimod: 7 year data from the LONGTERMS study [P591]. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Barcelona, Spain; 2015.
59.
• Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72:31–9. By retrospectively analyzing Phase 2 and 3 studies, Arvin and colleagues report an almost two fold increased rate of VZV infections in patients on fingolimod compared to those patients on placebo. Consequently, the authors recommend ascertaining a patient’s VZV immune status and vaccinating non-immune patients prior to treatment.CrossRefPubMed
60.
Ricklin ME, Lorscheider J, Waschbisch A, et al. T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology. 2013;81:174–81.CrossRefPubMed
61.
Achtnichts L, Obreja O, Conen A, et al. Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 2015;72:1203–5.CrossRefPubMed
62.
Huang D. Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Neurology. 2015;85:1001–3.CrossRefPubMed
63.
Forrestel AK, Modi BG, Longworth S, et al. Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 2016;73:355–6.CrossRefPubMed
64.
Kappos L, Radue EW, Comi G, et al. Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology. 2015;85:29–39.CrossRefPubMedPubMedCentral
65.
66.
67.
Fragoso YD, Brooks JB. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol. 2015;8:315–20.CrossRefPubMed
68.
O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–303.CrossRefPubMed
69.
Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–56.CrossRefPubMed
70.
Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18:1278–89.CrossRefPubMedPubMedCentral
71.
Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis. 2003;62:50–7.CrossRefPubMedPubMedCentral
72.
Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014;30:251–62.CrossRefPubMed
73.
Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–97.CrossRefPubMed
74.
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107.CrossRefPubMed
75.
Gold R, Giovannoni G, Phillips JT, et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler. 2015;21:57–66.CrossRefPubMedPubMedCentral
76.
Longbrake EE, Naismith RT, Parks BJ, et al. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015;1:2055217315596994.PubMedPubMedCentral
77.
Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, et al. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2015;2, e76.CrossRefPubMedPubMedCentral
78.
Gross CC, Schulte-Mecklenbeck A, Klinsing S, et al. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3, e183.CrossRefPubMed
79.
Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368:1657–8.CrossRefPubMed
80.
van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368:1658–9.CrossRefPubMed
81.
Dammeier N, Schubert V, Hauser TK, et al. Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol. 2015;15:108.CrossRefPubMedPubMedCentral
82.
• Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med. 2015;372:1476–8. Rosenkranz and colleagues report the first patient with RRMS who developed PML on dimethyl fumarate. The patient’s ALL was consistently < 600 cells/mm3. The case highlights the potential relationship between lymphopenia and PML risk with dimethyl fumarate.CrossRefPubMed
83.
84.
85.
Pfender N, Martin R. Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol. 2014;262 Pt A:44–51.CrossRefPubMed
86.
Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–75.CrossRefPubMed
87.
Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418–28.CrossRefPubMed
88.
Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord. 2016;9:36–46.CrossRefPubMed
Metadata
Title
Infectious Complications of Novel Multiple Sclerosis Therapies
Authors
S. N. Levin
T. B. Kaplan
Publication date
01-02-2017
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 2/2017
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-017-0562-0

Other articles of this Issue 2/2017

Current Infectious Disease Reports 2/2017 Go to the issue

Neurological Infections (J Lyons, Section Editor)

Neurologic Manifestation of Chikungunya Virus

Cardiovascular Infections (B Hoen, Section Editor)

Antibiotic Prophylaxis of Infective Endocarditis

Cardiovascular Infections (B Hoen, Section Editor)

Cardiac Imaging of Infective Endocarditis, Echo and Beyond

Neurological Infections (J Lyons, Section Editor)

The Viral Connection to Glioblastoma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits